Neurotech Opens First Site for Pivotal Autism Trial Targeting 150 Patients
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for paediatric neurological disorders. Their primary focus is on NTI164, a broad-spectrum oral cannabinoid drug therapy designed to address complex neurological conditions in children. With an exclusive worldwide license and extensive preclinical studies, the company has demonstrated potent anti-neuroinflammatory effects and committed to advancing treatments for conditions such as Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome.
The company has made significant strides in clinical research, completing Phase II/III randomized, double-blind, placebo-controlled clinical trials that have shown clinically meaningful and statistically significant benefits across multiple neurological disorders. Their research has yielded promising results, particularly in ASD, where they reported positive outcomes in treatment efficacy and safety. Neurotech has also received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy, highlighting their comprehensive approach to paediatric neurological treatment.
Committed to improving patient lives, Neurotech International aims to develop NTI164 as a prescription-only drug with rigorous scientific validation. Their strategy involves leveraging cannabinoid-based therapies to address unmet medical needs in paediatric neurological disorders, with a strong emphasis on research, clinical trials, and potential commercialization. The company is positioned at the forefront of innovative neurological treatment, seeking to provide hope and potential therapeutic solutions for children suffering from complex neurological conditions.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
